Research
Energy balance
Preliminary dose-dependent weight reductions were observed with KN069.
KN069 may help in achieving weight loss in this demographic.
StrongSupportsmedium confidence
In the SAD part, preliminary dose-dependent weight reductions were observed, with maximum early changes at Day 7 (90 mg: -4.71% vs. placebo: -0.41%).
Why this rating
Based on the randomized, double-blind trial design.
Source
A Phase 1, Randomised, Double‐Blind, Placebo‐Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of <scp>KN069</scp> (a Dual <scp>GLP</scp> ‐ <scp>1R</scp> Agonist and <scp>GIPR</scp> Antagonist) in Male Adults With Overweight or Obesity
Jinlian Xie et al. · Diabetes Obesity and Metabolism · 2026
DOI 10.1111/dom.70794
rct · n=48
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →